ACTEMRA PATIENT MONITORING AND MANAGEMENT 1

Ongoing monitoring of your patient is important during the treatment of a chronic disease. Some biologic agents used in the treatment of RA have guidelines for the management of changes in laboratory values. ACTEMRA patients should be monitored for changes in neutrophils, platelets, lipids, and hepatic transaminases, as changes in these parameters were associated with treatment with ACTEMRA. Dosage modifications may be required. This is not a complete list of the Important Safety Information for ACTEMRA. Please see full Prescribing Information, including BOXED WARNING, for additional Important Safety Information.

Hold ACTEMRA treatment if a patient develops a serious infection until the infection is controlled.
 

LIPIDS

LIVER FUNCTION TESTS (ALT/AST)

NEUTROPHILS

PLATELETS

ALT=alanine transaminase; AST=aspartate transaminase; DMARD=disease-modifying antirheumatic drug; HDL=high-density lipoprotein; LDL=low-density lipoprotein; RA=rheumatoid arthritis; SC=subcutaneous; ULN=upper limit of normal.